TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity

Jun Du, Zhiyuan Wu, Shurong Ren, Yong Wei, Meihua Gao, Gwendalyn J. Randolph, Chunfeng Qu

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

We previously reported that synthetic or natural Toll-like receptor (TLR) 7/8 agonists present within dead cells enhanced cell-associated antigen presentation both in vitro and in vivo. Here, we investigated the immunopotency of different chemically synthesized TLR7/8 agonists, Resiquimod, Gardiquimod, CL075, and CL097, on HBsAg immunogenicity. These agonists stimulated inflammatory monocyte-derived cells to become potent antigen-presenting dendritic cells (DCs), which augmented HBsAg specific T cell proliferation after they were conditioned with HBsAg. The TLR8 agonist CL075 and the TLR7/8 dual agonist CL097 showed more potent effects than the TLR7 agonist. Compared with alum adjuvant, when HBsAg mixed with CL075 was injected intramuscularly into mice, more monocyte-derived DCs carried antigens into draining lymph nodes and spleens. Specific Abs, particularly IgG2a, were significantly increased, and more IL-5 and IFN-γ were produced by splenocytes and intrahepatic immunocytes in mice that received HBsAg mixed with CL075 and CL097. These results suggest that TLR8 agonists are good candidates to enhance recombinant HBsAg immunogenicity to induce specific humoral and cellular immune responses.

Original languageEnglish
Pages (from-to)6273-6281
Number of pages9
JournalVaccine
Volume28
Issue number38
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Keywords

  • Cellular immune responses
  • Monocyte-derived dendritic cells
  • TLR8 agonists

Fingerprint Dive into the research topics of 'TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity'. Together they form a unique fingerprint.

Cite this